Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO,
N4 Pharma PLC (AIM:N4P) Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce an update on its current work
Open Orphan PLC (AIM:ORPH) Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan PLC (AIM:ORPH) Final results
Record revenues and EBITDA-profitability accompanied by significant operational progress
Open Orphan PLC (AIM:ORPH) GBP14.7m influenza contract signed
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that
4d Pharma PLC (AIM:DDDD) ASCO 2022 MRx0518 and Bavencio Trial In Progress
4D pharma Presents Trial in Progress Poster on the Phase II Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the
Open Orphan PLC (AIM:ORPH) Completion of Nominated Adviser due diligence
Open Orphan plc (AIM: ORPH), is a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials.
Deepverge Attends The UK Global Investor Show 2022 in London last weekend
A team from Deepverge presented at the UK Global Investor Show 2022 in London last weekend. Gerard Brandon, CEO, Camillus Glover, CFO, Paul Ryan, Chief Business Development Officer and Nicola
Open Orphan PLC (AIM:ORPH) Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Open Orphan PLC (AIM:ORPH) £7.3m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
4d Pharma PLC (AIM:DDDD) ATS 2022 – MRx-4DP0004 Phase I/II Part A poster
4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference